Moleculin Biotech Announces 1-for-20 Reverse Stock Split Effective October 20
Moleculin Biotech, Inc. (NASDAQ:MBRX) has filed a charter amendment in Delaware to execute a 1-for-20 reverse split of its common stock. The consolidation is scheduled to take effect at 12:01 a.m. Eastern Time on October 20, 2026. Shares will open for trading on a post-split basis on the Nasdaq Capital Market later that morning under the existing ticker symbol with a new CUSIP identifier.
Under the terms of the corporate action, every 20 pre-split shares will automatically convert into one share of common stock. The move will shrink the company's total outstanding shares from approximately 20.9 million to around 1.05 million, while keeping authorized common stock unchanged at 500 million shares. Stockholders who hold share totals not evenly divisible by 20 will receive cash payments in place of fractional shares.
The clinical-stage biopharmaceutical firm is developing treatments for hard-to-treat cancers and viruses, including its lead drug candidate Annamycin for acute myeloid leukemia. The company noted in its disclosure that it will require substantial additional funding to conduct its ongoing clinical trials and support its development goals.
Key points
- Moleculin Biotech, Inc. (NASDAQ:MBRX) is executing a 1-for-20 reverse stock split effective October 20, 2026.
- Post-split trading begins on the Nasdaq Capital Market on October 20 under ticker MBRX with a new CUSIP number.
- Total outstanding shares will fall from roughly 20.9 million to approximately 1.05 million.
- No fractional shares will be issued; eligible investors will receive cash payments instead.
- The company stated it will require significant additional financing to complete its planned clinical trials.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When will the Moleculin Biotech reverse stock split take effect?
The reverse stock split takes effect at 12:01 a.m. Eastern Time on October 20, 2026, with post-split trading starting at market open that day.
What is the split ratio for Moleculin Biotech's stock split?
The split ratio is 1-for-20, meaning every 20 existing shares will be consolidated into one single share of common stock.
What happens to fractional shares in the Moleculin reverse split?
No fractional shares will be issued. Stockholders entitled to a fraction of a share will receive a cash payment instead.